Foghorn Therapeutics (NasdaqGM:FHTX) FY Conference Transcript

Foghorn Therapeutics FY Conference Call Summary Company Overview - Company: Foghorn Therapeutics (NasdaqGM:FHTX) - Date of Call: October 30, 2025 - Focus: Updates on proprietary programs including selective ARID1B, CBP, and EP300 degraders [1][2][3] Key Industry Insights - Chromatin Regulatory System: Foghorn Therapeutics targets the chromatin regulatory system, which is implicated in cancer, with mutations found in up to 50% of tumors [4][5] - Market Opportunity: Successful drugs targeting this biology represent multi-billion-dollar opportunities [5] Core Programs and Developments 1. FHD-909 - Description: First-in-class selective oral small molecule inhibitor of SMARCA2, targeting tumors with SMARCA4 mutations [7] - Clinical Trial: Currently enrolling patients in a phase 1 dose escalation trial in the US and Japan, focusing on non-small cell lung cancer patients with SMARCA4 mutations [8] - Timeline: Anticipated decision on dose expansion by Lilly in the first half of 2026 [8] 2. Selective ARID1B Degrader - Significance: First to publicly demonstrate robust degradation of ARID1B, targeting a population with ARID1A mutations found in approximately 5% of solid tumors [9][10] - Clinical Context: ARID1A mutations accelerate tumor genesis and promote metastases, indicating a high unmet medical need [17] - Progress: Achieved 80% degradation in preclinical models, with in vivo proof of concept expected in 2026 [19][20] 3. Selective CBP Degrader - Target Population: Potential in EP300 mutated cancers and ER-positive breast cancer, with over 200,000 cases diagnosed annually in the US [24][25] - Mechanism: Selective degradation of CBP could provide a wider therapeutic window than dual CBP/EP300 inhibitors, avoiding hematological toxicities [24][27] - Development Status: Pre-development candidate CBP degrader (CPPD171) is on track for IND readiness in 2026 [10][28] 4. Selective EP300 Degrader - Target Indications: Significant potential in hematological malignancies, particularly multiple myeloma, with approximately 100,000 patients in the US potentially benefiting [31][32] - Clinical Validation: Previous dual CBP/EP300 inhibitors have shown compelling results in multiple myeloma, supporting the approach [34] - Development Timeline: Tracking towards IND-enabling studies in 2026 [38] Additional Insights - Mechanistic Understanding: Foghorn emphasizes a biology-first approach, focusing on novel biology and targets, with a deep mechanistic understanding of the chromatin regulatory system [5][6] - Partnership Strategy: The company is considering partnerships for larger tumor types, particularly in breast cancer and multiple myeloma, to leverage resources for clinical studies [80][81] - Feedback from Conferences: Positive feedback received on the selective degradation of ARID1B, indicating significant interest and curiosity from industry peers [83] Conclusion Foghorn Therapeutics is advancing a robust pipeline of selective degraders targeting critical components of the chromatin regulatory system, with significant potential to address unmet medical needs in various cancers. The company is on track for key milestones in 2026, including IND readiness for multiple programs.